Skip to Content

Clofarabine Dosage

Medically reviewed on February 27, 2017.

Applies to the following strengths: 1 mg/mL

Usual Adult Dose for Acute Lymphoblastic Leukemia

18 to less than 22 years:
52 mg/m2 IV over 2 hours daily for 5 consecutive days of a 28-day cycle; repeat every 2 to 6 weeks

Comments:
-Subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle.
-Subsequent cycles may be administered when the ANC is greater than or equal to 750/mm3.
-Provide supportive care, such as IV fluids, antihyperuricemics, and alkalinization of urine throughout therapy to reduce the risk of tumor lysis and other adverse events.
-Monitor renal, hepatic, and cardiac function during therapy.
-Monitor patients taking medications known to affect blood pressure.
-Discontinue therapy if hypotension develops during the 5 days of administration.

Use: For patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least 2 prior regimens

Usual Pediatric Dose for Acute Lymphoblastic Leukemia

1 year and older:
52 mg/m2 IV over 2 hours daily for 5 consecutive days of a 28-day cycle; repeat every 2 to 6 weeks

Comments:
-Subsequent cycles should begin no sooner than 14 days from day 1 of the previous cycle.
-Subsequent cycles may be administered when the ANC is greater than or equal to 750/mm3.
-Provide supportive care, such as IV fluids, antihyperuricemics, and alkalinization of urine throughout therapy to reduce the risk of tumor lysis and other adverse events.
-Monitor renal, hepatic, and cardiac function during therapy.
-Monitor patients taking medications known to affect blood pressure.
-Discontinue therapy if hypotension develops during the 5 days of administration.

Use: For patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least 2 prior regimens

Renal Dose Adjustments

-Mild renal dysfunction (CrCl 60 to less than 90 mL/min): No adjustment recommended.
-Moderate renal dysfunction (CrCl 30 to less than 60 mL/min): Reduce the starting dose by 50%.
-Severe renal dysfunction (CrCl less than 15 to less than 30 mL/min) and end stage renal disease (CrCl less than 15 mL/min): Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Supportive Medications and Medications to Avoid:
-Consider prophylactic antiemetic medications as this drug is moderately emetogenic.
-Consider the use of prophylactic steroids to mitigate Systemic Inflammatory Response Syndrome (SIRS) or capillary leak syndrome (e.g., hypotension, tachycardia, tachypnea, pulmonary edema).
-Minimize exposure to drugs with known renal toxicity during the 5 days of therapy since the risk of renal toxicity may be increased.
-Consider avoiding concomitant use of medications known to induce hepatic toxicity.

Dose Modifications and Reinitiation of Therapy:
HEMATOLOGIC TOXICITY:
-Administer subsequent cycles no sooner than 14 days from the starting day of the previous cycle and provided the patient ANC is 0.75 x 10(9)/L or greater.
-If a patient experiences a Grade 4 neutropenia (ANC less than 0.5 x 10(9)/L) lasting 4 weeks or more, reduce dose by 25% for the next cycle.
NONHEMATOLOGIC TOXICITY:
-Withhold therapy if the patient develops a clinically significant infection, until the infection is controlled, then restart at the full dose.
-Withhold therapy for Grade 3 noninfectious nonhematologic toxicity (excluding transient elevations in serum transaminases and/or serum bilirubin and/or nausea/vomiting controlled by antiemetic therapy); reinstitute therapy at a 25% dose reduction with resolution or return to baseline.
-Discontinue therapy for Grade 4 noninfectious nonhematologic toxicity.
-Discontinue therapy if a patient shows early signs or symptoms of SIRS or capillary leak (e.g., hypotension, tachycardia, tachypnea, pulmonary edema) occur and provide supportive measures.
-Discontinue therapy if Grade 3 or higher increases in creatinine or bilirubin are noted; reinstitute therapy at a 25% dose reduction, when the patient is stable and organ function has returned to baseline. If hyperuricemia is anticipated (tumor lysis), initiate measures to control uric acid.

Precautions

CONTRAINDICATIONS:
-None

Safety and efficacy have not been established in patients younger than 1 year or older than 21 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Therapy should be initiated and supervised by a physician experienced in the management of patients with acute leukemia.

Storage requirements:
-Store diluted product at room temperature (15C to 30C).

Reconstitution/preparation techniques:
-Filter through a sterile 0.2-micron syringe filter and dilute with 5% dextrose injection or 0.9% sodium chloride injection prior to IV infusion to a final concentration between 0.15 and 0.4 mg/mL.
-Use within 24 hours of preparation.

IV compatibility:
-Do not administer any other medications through the same IV line.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide